European Patent Office Revokes Patent for Cellergy Nitroglycerin Ointment

Law360, New York (December 15, 2003, 12:00 AM EST) -- The European Patent Office revoked a European Patent for a nitroglycerin ointment held by Cellegy Pharmaceuticals, the company said Monday.

The Board of Opposition of the European Patent Office rendered a verbal decision revoking Cellegy's European patent relating to its Cellegesic product and related compounds for the treatment of anal disorders, including fissures and various hemorrhoidal conditions, according to the company.

Oppositions to the issued patent had previously been filed with the European Patent Office, and the verbal decision followed an oral proceeding before the Board....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.